Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)

Part of paid clinical trials in Bakersfield, California.

Sponsor
California Retina Consultants
Study ID
NCT00729846
Phase
PHASE2
Status
Completed

Conditions

  • Age Related Macular Degeneration
  • Choroidal Neovascularization
  • Macular Edema

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To evaluate safety, visual acuity outcomes, persistence of choroidal neovascular leakage, and the number of treatments of combination intravitreal bevacizumab and verteporfin photodynamic therapy at standard or reduced fluence level in patients with subfoveal CNV due to age-related macular degeneration.

Key Dates

First listed
Aug 8, 2008
Start date
May 31, 2006
Status verified
Mar 2016
Primary completion
Aug 31, 2008
Completion
Jul 31, 2009

Study Design

Enrollment
22 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: A
    Patients will receive combination verteporfin with photodynamic therapy at reduced fluence \[300mw/cm2\] followed by intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
  • Experimental: B
    Patients will receive combination verteporfin with photodynamic therapy at standard fluence \[600mw/cm2\] followed by intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.

Primary Outcome Measure

Visual Acuity: Percentage of Patients Losing 3 or More Lines(15 Letters) of Visual Acuity From Baseline. [ Time Frame: 1 Year ]

Locations (2)

FacilityCityStateZIPSite coordinators
California Retina ConsultantsBakersfieldCalifornia93309-
California Retina ConsultantsSanta BarbaraCalifornia93103-

Find similar trials in Bakersfield, CA

By research site
California Retina Consultants· Bakersfield, CACalifornia Retina Consultants· Santa Barbara, CA

Related Studies